Research programme: androgen receptor antagonists - Medivation

Drug Profile

Research programme: androgen receptor antagonists - Medivation

Alternative Names: MDV 300 series; MDVN 300 series

Latest Information Update: 23 Mar 2012

Price : $50

At a glance

  • Originator University of California at Los Angeles
  • Developer Medivation
  • Class Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 23 Mar 2012 No development reported - Preclinical for Prostate cancer in USA (unspecified route)
  • 29 Jun 2007 Medivation receives clearance from the FDA to commence a phase I/IIa trial of MDV 3100 in hormone-refractory prostate cancer
  • 01 Mar 2007 Preclinical data added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top